Bruker and 10x Genomics have recently come to an agreement to settle a patent dispute that originated from products initially developed by Nanostring, a company that Bruker acquired in 2024. This settlement includes global cross-license agreements for their respective patents and the withdrawal of all ongoing lawsuits and administrative proceedings in the US, Germany, and before the European Unified Patent Court.
The patent dispute between the two companies began when 10x Genomics filed a lawsuit in 2023, claiming that Nanostringâs GeoMx Digital Spatial Profiler, a product used to profile the spatial distribution of RNA and protein expression in tissue samples, infringed on seven patents. In November of the same year, the district court of Delaware ruled in favor of 10x Genomics.
Following Nanostring’s bankruptcy in February 2024, Bruker acquired the company for $392.6 million and inherited the lawsuit. In December 2024, Delaware’s district court upheld damages of $31.6 million against Bruker, but declined the enhanced damages requested by 10x Genomics. The court also granted an injunction requested by 10x Genomics, halting the sales of GeoMx products to new customers in the US.
Todd Garland, president of Bruker’s spatial biology division, expressed the company’s intention to seek a stay on the injunction and looked forward to appealing the case to the US Court of Appeals for the Federal Circuit. Mark Munch, president of the Bruker Nano Group, commented on the settlement agreement, stating that the company was relieved to put the distractions and expenses of the legal cases behind them.
Munch added that the settlement was a positive outcome for the scientific community, allowing researchers to continue using Bruker’s CosMx and GeoMx spatial biology platforms without concerns of litigation interfering with their work in fields such as oncology and neurobiology.
The agreement between Bruker and 10x Genomics marks the end of all litigation between the two companies, providing a resolution that benefits both parties and the scientific community at large. This news was originally reported by Medical Device Network, a GlobalData owned brand.
Please note that the information provided in this article is for general informational purposes only and should not be relied upon as advice. It is recommended to seek professional or specialist advice before making any decisions based on the content provided.
